Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Patients with rapidly progressive alopecia areata often have a better outlook and shorter disease duration, with regrown fine hairs and no past alopecia being positive signs.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Current corticosteroid pulse therapy is not very effective for severe rapidly progressive alopecia areata.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Two patients with stubborn hair loss grew hair after PDRN injections.

AIRE-deficient rats developed severe autoimmune disease similar to APECED, useful for testing treatments.

A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.

People with alopecia areata have higher levels of RBP4 protein and antibodies against it.

Non-coding RNA boosts retinoic acid production and signaling, aiding regeneration.

LLPS is crucial for RALF signaling, aiding plant growth and stress resilience.

Ritlecitinib shows promise in improving severe alopecia areata, with 27% of patients seeing success.

The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Higher RBP4 levels found in people with two types of hair loss.

PPAR-γ may be a key target for treating alopecia areata and other skin conditions.

Regional prescribing of ritlecitinib mostly follows national guidance, but psychological assessments and consistent scoring need improvement.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

The combination of PRP and triamcinolone injections improved hair growth in a man with alopecia areata.

Ritlecitinib is safe for treating alopecia areata for up to 48 weeks.

Ritlecitinib shows promise for treating alopecia areata with significant hair regrowth and no serious side effects.

Ritlecitinib improves hair growth and quality of life in severe alopecia areata with longer use.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

The AIRE gene variant rs2075876 is linked to a higher risk of alopecia areata in males.

PPARα agonists may help treat alopecia areata by reducing inflammation.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.